Skin mucormycosis in dermatological practice: dangerous coinfection during the covid-19 pandemic (Current state of the issue)

The coronavirus SARS-COV-2 pandemic has caused an increase in the incidence of the population and significant losses that have claimed more than 6.8 million lives worldwide. In recent years, secondary microbial co-infections have caused serious concern: Influenza, tuberculosis, typhoid fever, mucormycosis, etc. At the beginning of the catastrophic wave of coronavirus disease, there were reports of a rare but deadly mucormycosis, which quickly spread throughout the world. Currently, the relevance of this complication has increased significantly due to the pandemic of a new coronavirus infection, immunosuppression, diabetes mellitus and the massive use of glucocorticosteroids for the treatment of COVID-19. It is proposed to revise diagnostic strategies to detect secondary co-infection. First-line therapy is amphotericin B in combination with surgery. Delaying antifungai therapy and surgical excision of diseased tissue increases mucormycosisrelated mortality, requiring a high level of medical skill in both diagnostic and therapeutic aspects. © 2023, Eco-Vector LLC. All rights reserved.